Meeting report: Advancing accelerated regulatory review with Real-Time Oncology Review (RTOR), Project Orbis, and the Product Quality Assessment Aid
Tóm tắt
The American Association of Pharmaceutical Scientists (AAPS) Chemistry, Manufacturing, and Controls (CMC) Community hosted two virtual panel discussions focusing on several novel regulatory review pathways for innovative oncology products: Real-Time Oncology Review (RTOR), Project Orbis, and the Product Quality Assessment Aid (PQAAid). The panel sessions were held on August 27, 2021, for the discussion of RTOR, and January 21, 2022, for the discussion of Project Orbis and the PQAAid. Both panel sessions included representatives from the US Food and Drug Administration (FDA) and subject matter experts from the pharmaceutical and biotechnology industries, with the aim of facilitating knowledge sharing on CMC-specific advantages, challenges, eligibility criteria for participation, and operational modifications instituted through the utilization of these acceleration initiatives. Key topics included managing cross-regional regulatory CMC requirements, adapting to expedited development timelines, coordinating interactions between health authorities and industry, and potential opportunities for future improvement and expansion of these programs. As RTOR, Project Orbis, and PQAAid are relatively new initiatives, the experiences shared by the panel experts are valuable for providing deeper insight into these new regulatory pathways and processes.
Tài liệu tham khảo
Brown DG et al (2021) Clinical development times for innovative drugs. Nat Rev Drug Discov. https://doi.org/10.1038/d41573-021-00190-9
de Claro RA et al (2020) Project Orbis: global collaborative review program. Clin Cancer Res 26(24):6412–6416
de Claro RA et al (2021) U.S. Food and Drug Administration: initial experience with the Real-Time Oncology review program. Clin Cancer Res 27(1):11–14
Helwick, C. Delays in drug approval are deadly, highlighting the need for improved regulatory efficiency. 2015; Available from: https://ascopost.com/issues/october-25-2015/delays-in-drug-approval-are-deadly-highlighting-the-need-for-improved-regulatory-efficiency/. Accessed 10 Apr 2022.
Kepplinger EE (2015) FDA’s expedited approval mechanisms for new drug products. Biotechnol Law Rep 34(1):15–37
Narayan P et al (2020) Project Orbis: partnering with international regulatory agencies to bring earlier global access to novel cancer treatments. Available from: https://ascopost.com/issues/december-10-2020/project-orbis-partnering-with-international-regulatory-agencies-to-bring-earlier-global-access-to-novel-cancer-treatments/. Accessed 4 Apr 2022
Pharmaceutical Research and Manufacturers of America (PhRMA). Accelerated approval: bringing patients access to needed medicines. Available from: https://phrma.org/-/media/Project/PhRMA/PhRMA-Org/PhRMA-Org/PDF/A-C/Accelerated-approval%2D%2DBringing-patients-access-to-needed-medicines-2.pdf. Accessed 22 Feb 2022
US Food and Drug Administration (2011) Guidance for industry process validation: general principles and practices. Available from: https://www.fda.gov/files/drugs/published/Process-Validation-General-Principles-and-Practices.pdf. Accessed 22 Mar 2022
US Food and Drug Administration (2014) Guidance for industry: expedited programs for serious conditions – drugs and biologics. Available from: https://www.fda.gov/files/drugs/published/Expedited-Programs-for-Serious-Conditions-Drugs-and-Biologics.pdf. Accessed 15 Mar 2022
US Food and Drug Administration (2021) Assessment aid. Available from: https://www.fda.gov/about-fda/oncology-center-excellence/assessment-aid. Accessed 4 Apr 2022
US Food and Drug Administration (2022a) Oncology center of excellence. Available from: https://www.fda.gov/about-fda/fda-organization/oncology-center-excellence. Accessed 22 Mar 2022
US Food and Drug Administration (2022b) Project Orbis. Available from: https://www.fda.gov/about-fda/oncology-center-excellence/project-orbis. Accessed 4 Apr 2022
Yu LX et al (2014) Understanding pharmaceutical quality by design. AAPS J 16(4):771–783